PURE · Pure Bioscience, Inc.
$0.06
-0.02 (-22.50%)
At close · Sep 2
Going-concern doubt
— flagged Jun 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our history of recurring operating losses, and negative cash flows from operating activities give rise to substantial doubt regarding our ability to continue as a going concern.”View the 10-Q filed Jun 15, 2026
Market Cap
$10.40M
Shares
130.02M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Tom Myers | Executive Vice President of Technology & Development | $197,400 |
| Robert Bartlett | Chief Executive Officer | $191,300 |
| Mark Elliott | Vice President Finance | $178,600 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Tom Myers | Executive Vice President of Technology & Development | $215,000 |
| Robert Bartlett | Chief Executive Officer | $215,000 |
| Mark Elliott | Vice President Finance | $195,000 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Tom Myers | Executive Vice President of Technology & Development | $237,000 |
| Mark Elliott | Vice President Finance | $195,000 |
| Robert Bartlett | Chief Executive Officer | $129,800 |
| Tom Y. Lee | Chief Executive Officer | $92,000 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Tom Myers | Executive Vice President of Technology & Development | $200,000 |
| Mark Elliott | Vice President Finance | $180,000 |
| Tom Y. Lee | Chief Executive Officer | $74,000 |
| Robert Bartlett | Chief Executive Officer | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Tom Myers | Chief Operating Officer | $231,000 |
| Mark Elliott | Vice President Finance | $189,000 |
| Tom Y. Lee | Chief Executive Officer | $164,000 |